Apellis Pharmaceuticals Inc
222 articles about Apellis Pharmaceuticals Inc
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2023
1/6/2023
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 10 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
1/5/2023
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer.
-
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Apellis Pharmaceuticals, Inc. announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT / 12:00 p.m. ET.
-
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
12/16/2022
Apellis Pharmaceuticals, Inc. today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 07, 2022
12/7/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to two new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - November 22, 2022
11/22/2022
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the company will participate in the following investor conferences.
-
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
11/18/2022
Apellis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted Apellis’ unsolicited major amendment to the New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
11/7/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2022 financial results and business highlights.
-
Apellis is submitting additional 24-month efficacy data to supplement the NDA for its intravitreal candidate pegcetacoplan for GA secondary to AMD.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 04, 2022
11/4/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 7 new employees with a grant date of November 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
11/3/2022
Apellis Pharmaceuticals, Inc. announced that results from the long-term extension study of EMPAVELI® in adults with paroxysmal nocturnal hemoglobinuria will be presented at the American Society of Hematology Annual Meeting being held Dec. 10-13 in New Orleans, Louisiana.
-
Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)
11/3/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
10/31/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its third quarter 2022 financial results on Monday, November 7, 2022 at 4:30 p.m. ET.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 07, 2022
10/7/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 8 new employees with a grant date of October 3, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Gene therapies developed by Janssen, Atsena, REGENXBIO and AbbVie showed promise against eye diseases this weekend at the American Academy of Ophthalmology 2022 meeting.
-
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
9/30/2022
Apellis Pharmaceuticals, Inc. announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan, an investigational targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.
-
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
9/12/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fireside chat at an upcoming investor conference hosted by Bank of America.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 07, 2022
9/7/2022
Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 64 new employees with a grant date of September 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
-
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
8/24/2022
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced top-line data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).